Among these, the thymidine kinase (TK)/Flt3 ligand (Flt3L) gene therapy has emerged as a powerful strategy to enhance anti-tumor immunity and prolong survival in preclinical models37. This evidence concerns the gene FLT3LG and neoplasm.